SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534
United States
661-723-7723
http://www.simulations-plus.com

SectorTechnology
IndustryHealth Information Services
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Mr. Walter S. WoltoszCo-Founder, Chairman & Advisor223.2kN/A1945
Mr. Shawn M. O'ConnorChief Exec. OfficerN/AN/A1960
Mr. John R. KneiselChief Financial Officer187.94kN/A1958
Ms. Cynthia WalawanderVP of OperationsN/AN/AN/A
Ms. Virginia E. WoltoszSec. & TreasurerN/AN/A1951
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application, which organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; and DILIsym, a software that is used to investigate the likelihood that a known drug molecule would cause injury to the liver. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and for submissions to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Additionally, it offers its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, and food companies. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.

Corporate Governance

Simulations Plus, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 6. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.